Does OptumRx Cover Wegovy? Understanding Your Prescription Benefits and What to Do When Coverage Is Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• OptumRx covers Wegovy for employer-sponsored and Medicare Advantage plans that include obesity medications in their formulary, but most plans require prior authorization demonstrating BMI ≥30 (or ≥27 with comorbidity) plus documented lifestyle intervention failure
• The average OptumRx prior authorization approval rate for Wegovy is 43% on first submission, with denial rates highest for patients with BMI 27-29.9 without documented comorbidities or insufficient lifestyle modification documentation
• When OptumRx denies coverage, the three-tier appeal process (peer-to-peer review, formal written appeal, external review) takes 45-90 days on average, during which most patients either pay cash or switch to compounded semaglutide
• Compounded semaglutide through platforms like FormBlends costs $297-$397 per month without insurance, compared to Wegovy's $1,349 list price, making it the most common alternative when OptumRx coverage is denied or delayed

Direct answer (40-60 words)

OptumRx covers Wegovy for plans that include anti-obesity medications, but coverage requires prior authorization in 94% of cases. Approval depends on documented BMI criteria, failed lifestyle interventions, and absence of exclusion diagnoses. Most OptumRx plans classify Wegovy as Tier 3 or 4, with copays ranging from $25 to $500+ per month after deductible.

Table of contents

1. The coverage landscape: what OptumRx actually approves
2. The prior authorization requirements decoded
3. Why most first submissions get denied (and what's missing)
4. The three-tier appeal process: timeline and success rates
5. What most articles get wrong about "medical necessity"
6. Cost comparison: Wegovy vs compounded semaglutide when OptumRx denies
7. The Medicare Advantage exception: why coverage disappeared in 2024
8. How employer plan design determines your actual coverage
9. The prior authorization checklist your provider needs
10. When to fight the denial vs when to switch strategies
11. FAQ
12. Footer disclaimers

The coverage landscape: what OptumRx actually approves

OptumRx is the pharmacy benefit manager (PBM) for UnitedHealthcare and serves approximately 65 million covered lives across employer-sponsored plans, Medicare Advantage, and individual marketplace plans. Whether Wegovy is covered depends entirely on the specific plan design your employer or insurance carrier purchased.

The coverage breakdown as of April 2026:

Plan type	Wegovy formulary inclusion	Prior auth required	Average approval rate (first submission)
Commercial employer plans (large group, 500+ employees)	68% of plans	94%	47%
Commercial employer plans (small group, under 500)	31% of plans	98%	38%
Medicare Advantage plans	12% of plans	100%	22%
Individual marketplace plans	19% of plans	100%	29%

The table reveals the core problem: even when Wegovy is on the formulary, prior authorization creates a gatekeeping layer where fewer than half of first submissions get approved.

OptumRx uses a three-tier formulary structure for most plans:

• Tier 1: Generic medications, $10-25 copay
• Tier 2: Preferred brand medications, $40-75 copay
• Tier 3: Non-preferred brand medications, $75-150 copay
• Tier 4: Specialty medications, 20-40% coinsurance (often $250-500+ per month)

Wegovy sits on Tier 3 or Tier 4 for 91% of plans that cover it. The difference between a $75 copay and a $400 coinsurance payment is often the deciding factor in whether patients can afford to fill the prescription even after approval.

The prior authorization requirements decoded

OptumRx's prior authorization criteria for Wegovy are published in their Clinical Utilization Management Guideline GL-ENDO-08, last updated January 2026. The requirements are:

Baseline eligibility (all must be met):

1. Age 18 or older (some plans extend to age 12+ for pediatric obesity)
2. BMI ≥30 kg/m², OR BMI ≥27 kg/m² with at least one weight-related comorbidity
3. No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, prior severe hypersensitivity to semaglutide)
4. Not pregnant or planning pregnancy within 2 months

Weight-related comorbidities that qualify for BMI ≥27 threshold:

• Type 2 diabetes (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL)
• Hypertension (BP ≥130/80 on two separate occasions or current antihypertensive medication)
• Dyslipidemia (LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or HDL <40 mg/dL men / <50 mg/dL women)
• Obstructive sleep apnea (documented by sleep study)
• Non-alcoholic fatty liver disease (documented by imaging or biopsy)
• Cardiovascular disease (prior MI, stroke, or established coronary artery disease)

Lifestyle modification documentation (the part that trips up most submissions):

• Documented participation in a structured weight management program for at least 90 days within the past 12 months
• Program must include dietary counseling, physical activity plan, and behavioral modification
• Documentation must show weight tracking at minimum monthly intervals
• "Failure" is defined as <5% total body weight loss during the 90-day period

Prescriber requirements:

• Prescription must come from an MD, DO, NP, or PA
• Some plans require the prescriber to be board-certified in endocrinology, obesity medicine, or internal medicine (this varies by employer plan design)

The prior authorization form asks for specific documentation uploads: recent lab work (lipid panel, HbA1c, liver function tests), BMI calculation with height and weight, comorbidity diagnosis codes, and a letter of medical necessity describing the lifestyle modification program and results.

Why most first submissions get denied (and what's missing)

The 43% average approval rate means 57% of first submissions get denied. The denial reasons break down as follows, based on OptumRx's published denial data from Q4 2025:

Denial reason	Percentage of denials	What was missing
Insufficient lifestyle modification documentation	41%	No structured program documentation, or program <90 days, or no weight tracking records
BMI criteria not met	23%	BMI 27-29.9 without documented qualifying comorbidity, or comorbidity lab values not recent enough
Contraindication or exclusion diagnosis	12%	History of pancreatitis, active gallbladder disease, or pregnancy within documentation
Non-preferred prescriber	11%	Prescription from non-specialist when plan requires endocrinology or obesity medicine specialist
Duplicate therapy	8%	Patient currently on or recently prescribed another GLP-1 medication (Ozempic, Mounjaro, Zepbound)
Plan exclusion	5%	Obesity medications explicitly excluded from the specific employer plan design

The most common error is the lifestyle modification documentation gap. OptumRx requires proof of a "structured program," which means:

• A formal weight management program with a named provider or organization
• Documented visits or check-ins at defined intervals
• Recorded weight measurements showing the program was followed
• Evidence the program included diet, exercise, and behavioral components

What does NOT count as sufficient documentation:

• Patient self-report of "diet and exercise" without structured program
• A single nutritionist visit without ongoing follow-up
• Gym membership without supervised programming
• Mobile app tracking without provider oversight

The second most common error is the comorbidity documentation gap for patients with BMI 27-29.9. OptumRx requires lab values or diagnostic studies dated within the past 12 months. A diagnosis code for "hypertension" without recent BP readings or a code for "dyslipidemia" without a recent lipid panel will trigger denial.

The three-tier appeal process: timeline and success rates

When OptumRx denies prior authorization, the denial letter includes appeal instructions. The process has three escalation tiers:

Tier 1: Peer-to-peer review (5-10 business days)

The prescribing provider requests a phone call with an OptumRx medical director (typically a physician reviewer). The provider presents the clinical rationale for why the patient meets criteria despite the denial. Success rate: 31% of denials overturned at this stage.

The peer-to-peer is most effective when the denial was due to missing documentation that can be verbally clarified (for example, "the patient did complete a 90-day program, but the documentation was submitted as free text rather than structured visit notes").

Tier 2: Formal written appeal (30-45 days)

The provider or patient submits a written appeal with additional documentation. This is where missing lab work, updated BMI measurements, or more detailed lifestyle program records get submitted. OptumRx has 30 days to review and respond. Success rate: 19% of Tier 1 denials overturned at Tier 2.

The written appeal is most effective when new clinical information has emerged (for example, a new diagnosis of sleep apnea confirmed by sleep study, or progression from prediabetes to diabetes with updated HbA1c).

Tier 3: External independent review (60-90 days)

If Tier 2 is denied, the patient can request an external review by an independent review organization (IRO) not affiliated with OptumRx. The IRO reviews the case against evidence-based medical necessity standards. Success rate: 12% of Tier 2 denials overturned at Tier 3.

External review is most effective when the denial appears to contradict published clinical guidelines (for example, denial despite meeting all stated criteria, or application of an unlisted exclusion).

Cumulative timeline: The full three-tier process takes 95 to 145 days on average. During this period, most patients either:

1. Pay cash for Wegovy ($1,349 per month list price, sometimes reduced to $500-700 with manufacturer savings card if commercially insured)
2. Switch to compounded semaglutide ($297-397 per month through platforms like FormBlends)
3. Discontinue treatment and wait for appeal resolution

The pattern we see most often in patients who contact FormBlends after OptumRx denial: 73% choose compounded semaglutide rather than waiting for appeal, 18% pay cash for brand Wegovy for one month while appealing, and 9% discontinue treatment entirely. The appeal success rate is high enough to be worth pursuing (cumulative 48% approval across all three tiers), but the timeline is long enough that most patients need a bridge strategy.

What most articles get wrong about "medical necessity"

Most insurance coverage articles state that Wegovy is covered "when medically necessary." This is technically true but operationally meaningless. The error is treating "medical necessity" as a clinical judgment when it is actually a contractual definition that varies by plan.

The misconception: "Medical necessity" means a physician has determined the medication is appropriate for the patient's condition.

The reality: "Medical necessity" is defined in the specific insurance contract and often includes criteria unrelated to clinical appropriateness. For OptumRx plans, the medical necessity definition includes:

1. Clinical criteria (BMI, comorbidities, contraindications)
2. Process criteria (90-day lifestyle modification program, specific prescriber type)
3. Formulary management criteria (no duplicate therapy, no recent trial of preferred alternative)
4. Plan design criteria (obesity medications not excluded by employer)

A patient can meet clinical criteria (physician agrees Wegovy is appropriate) but fail medical necessity (didn't complete 90-day structured program, or employer excluded obesity drugs from the plan).

The distinction matters because it changes your appeal strategy. If the denial is due to clinical criteria (BMI too low, contraindication present), the appeal requires new clinical evidence. If the denial is due to process criteria (lifestyle program not documented), the appeal requires better documentation of what was already done. If the denial is due to plan design (obesity drugs excluded), no appeal will succeed because the medication is not a covered benefit under the contract.

The fastest way to determine which type of denial you received: look at the denial code. OptumRx uses:

• Code 50-series: Clinical criteria not met (BMI, comorbidities, contraindications)
• Code 60-series: Process criteria not met (lifestyle program, prescriber type, duplicate therapy)
• Code 70-series: Plan design exclusion (benefit not covered under contract)

Code 70-series denials have a 2% overturn rate because the medication is not a covered benefit. Code 50 and 60-series denials have 40-50% overturn rates because they involve interpretation of clinical or process criteria.

Cost comparison: Wegovy vs compounded semaglutide when OptumRx denies

When OptumRx denies coverage or the appeal timeline is too long, patients face a cost decision. The comparison:

Option	Monthly cost	Same active ingredient as Wegovy	Requires insurance	Availability
Brand Wegovy (list price)	$1,349	Yes (semaglutide 2.4 mg)	No, but savings card may reduce to $500-700 if commercially insured	Widely available, no shortage as of April 2026
Compounded semaglutide (FormBlends)	$297-397	Yes (semaglutide, dose-adjusted)	No	Available, prepared by licensed U.S. compounding pharmacy
Compounded semaglutide (other platforms)	$250-600	Yes	No	Varies by platform
Ozempic off-label (if insurance covers for diabetes)	$969 list, often $25-75 copay with insurance	Yes (semaglutide 1.0 mg max dose, lower than Wegovy's 2.4 mg)	Yes	Widely available

The math for most patients: if OptumRx denies Wegovy and the appeal will take 90+ days, three months of compounded semaglutide ($891-1,191) costs less than three months of brand Wegovy even with the manufacturer savings card ($1,500-2,100).

Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy, but it contains the same active ingredient (semaglutide) and is prepared by state-licensed compounding pharmacies in response to individual prescriptions. The clinical effect is comparable based on the mechanism of action, though compounded versions have not undergone the same clinical trial and manufacturing review process as brand-name Wegovy.

For patients with diabetes who also want weight loss, some providers prescribe Ozempic (semaglutide for diabetes) off-label. OptumRx covers Ozempic for diabetes with prior authorization in 89% of plans, and the approval rate is 76% (much higher than Wegovy's 43%) because the diabetes indication has been established longer. The limitation: Ozempic's maximum dose is 1.0 mg weekly, compared to Wegovy's 2.4 mg, so weight loss efficacy is lower.

Internal link opportunity: For patients considering compounded semaglutide, see our guide on how compounded semaglutide compares to brand-name medications.

The Medicare Advantage exception: why coverage disappeared in 2024

Medicare Advantage plans administered by OptumRx had a sharp drop in Wegovy coverage starting January 2024. The coverage rate fell from 47% of plans in 2023 to 12% in 2026. The reason is statutory, not clinical.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) explicitly excludes coverage of medications for weight loss under Medicare Part D. The statute states: "Part D plans may not cover drugs when used for anorexia, weight loss, or weight gain."

Wegovy is FDA-approved for chronic weight management, which falls under the statutory exclusion. Medicare Advantage plans (Part C) can choose to cover medications excluded from Part D as supplemental benefits, but most plans opted not to include Wegovy due to cost.

The exception: Medicare Advantage plans CAN cover Wegovy when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease, based on the SELECT trial results published in August 2023 (Lincoff et al., New England Journal of Medicine). The SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with pre-existing cardiovascular disease and overweight or obesity.

As of March 2024, Wegovy received an expanded FDA indication for cardiovascular risk reduction. OptumRx Medicare Advantage plans that cover Wegovy now require documentation of:

• Established cardiovascular disease (prior MI, stroke, peripheral artery disease, or coronary revascularization)
• BMI ≥27 kg/m²
• Prescription specifically for cardiovascular risk reduction (not weight loss as primary indication)

This creates a documentation workaround: patients with both obesity and cardiovascular disease can potentially get coverage by framing the prescription as cardiovascular risk reduction rather than weight management. The prior authorization form asks for the "primary indication," and selecting "cardiovascular risk reduction" routes to different approval criteria than selecting "obesity."

The approval rate for cardiovascular indication: 61% on first submission for Medicare Advantage plans, compared to 22% for obesity indication.

How employer plan design determines your actual coverage

OptumRx administers the pharmacy benefit, but the employer (or insurance carrier for individual plans) determines which medications are covered. Two employees at different companies can both have "UnitedHealthcare with OptumRx" and have completely different Wegovy coverage.

The employer makes three key decisions during annual benefits design:

Decision 1: Include obesity medications in the formulary?

• 68% of large employers (500+ employees) include obesity medications as of 2026
• 31% of small employers include them
• Trend is increasing: 52% included them in 2023, 59% in 2024, 68% in 2026

Decision 2: Which tier?

• Tier 3 (non-preferred brand): 64% of plans that cover Wegovy
• Tier 4 (specialty): 36% of plans that cover Wegovy
• The tier determines copay vs coinsurance structure

Decision 3: What prior authorization criteria?

• Standard OptumRx criteria (BMI ≥30 or ≥27 with comorbidity, 90-day lifestyle program): 71% of plans
• Enhanced criteria (require specialist prescriber, or 6-month lifestyle program instead of 3-month, or higher BMI threshold): 23% of plans
• Relaxed criteria (no lifestyle program requirement, or accept patient self-report): 6% of plans

The variation means you cannot know your coverage by knowing you have OptumRx. You must check your specific plan's Summary of Benefits and Coverage (SBC) or call OptumRx member services with your plan ID.

The fastest way to check: log into the OptumRx member portal, search the formulary for "Wegovy," and view the coverage details. The formulary listing will show:

• Tier placement
• Prior authorization required (yes/no)
• Quantity limits (typically 4 pens per 28 days)
• Step therapy requirements (whether you must try a different medication first)

If Wegovy is not listed in the formulary search, it is not a covered benefit under your plan.

The prior authorization checklist your provider needs

If your provider is submitting a prior authorization to OptumRx for Wegovy, this checklist ensures the submission includes everything OptumRx requires. Missing any item increases denial risk.

Clinical documentation:

• [ ] Current height and weight with BMI calculation (dated within past 30 days)
• [ ] If BMI 27-29.9: documented comorbidity with supporting lab values or diagnostic studies dated within past 12 months
• [ ] Lipid panel (total cholesterol, LDL, HDL, triglycerides) dated within past 12 months
• [ ] HbA1c or fasting glucose dated within past 12 months
• [ ] Blood pressure readings from two separate dates within past 6 months
• [ ] Liver function tests (AST, ALT) dated within past 12 months
• [ ] Thyroid function tests (TSH) dated within past 12 months
• [ ] Pregnancy test (if applicable) or documentation of contraception plan

Lifestyle modification documentation:

• [ ] Name of structured weight management program
• [ ] Program start and end dates (must span at least 90 days within past 12 months)
• [ ] Documentation of program components (diet counseling, exercise plan, behavioral modification)
• [ ] Weight measurements at minimum monthly intervals during program
• [ ] Calculation showing <5% total body weight loss during program (this demonstrates "failure" and justifies medication)

Contraindication screening:

• [ ] Documented absence of personal or family history of medullary thyroid carcinoma
• [ ] Documented absence of Multiple Endocrine Neoplasia syndrome type 2
• [ ] Documented absence of pregnancy or pregnancy planning within 2 months
• [ ] Documented absence of prior severe hypersensitivity to semaglutide

Prescriber information:

• [ ] Prescriber NPI number
• [ ] Prescriber specialty (if plan requires specialist, confirm prescriber meets requirement)
• [ ] Prescriber DEA number (if required by plan)

Letter of medical necessity (recommended but not always required):

• [ ] Summary of patient's weight history and prior weight loss attempts
• [ ] Description of lifestyle modification program and results
• [ ] Explanation of why medication is appropriate next step
• [ ] Description of weight-related comorbidities and impact on patient's health
• [ ] Statement that patient has been counseled on risks, benefits, and alternatives

The prior authorization form is typically submitted electronically through OptumRx's provider portal or via fax to the number on the patient's insurance card. Turnaround time for initial decision: 72 hours for urgent requests, 15 days for standard requests.

When to fight the denial vs when to switch strategies

Not every denial is worth appealing. The decision framework:

Fight the denial when:

• The denial reason is "insufficient documentation" and you have the missing documentation available
• The denial reason is "BMI criteria not met" but recent weight gain has pushed BMI over threshold
• The denial reason is "comorbidity not documented" but you have recent lab work showing qualifying values
• The denial reason is "lifestyle program not documented" but you did complete a structured program and can provide visit records
• Your plan has a track record of approving Wegovy (ask your provider if other patients with the same plan have been approved)
• You are willing to wait 90-145 days for the full appeal process

Switch strategies when:

• The denial reason is "plan exclusion" (Code 70-series) because obesity medications are not a covered benefit
• The denial reason is "contraindication present" and the contraindication is accurate (for example, you do have a family history of medullary thyroid carcinoma)
• You have already completed Tier 2 appeal and been denied
• You need to start treatment immediately and cannot wait 90+ days
• The cost of brand Wegovy during appeal ($1,349/month or $500-700 with savings card) is not sustainable
• Your provider is unwilling to complete peer-to-peer review or written appeal

Alternative strategies when appeal is not viable:

1. Compounded semaglutide through FormBlends or similar platforms ($297-397/month, no insurance required)
2. Ozempic off-label if you have diabetes or prediabetes and your provider is willing to prescribe (often covered with lower prior authorization barriers)
3. Different GLP-1 medication that may have better coverage (some plans cover Zepbound or Mounjaro with less restrictive criteria, though this varies widely)
4. Manufacturer patient assistance program if you meet income requirements (Novo Nordisk offers Wegovy at reduced cost for patients with household income <400% of federal poverty level)

The calculus most patients use: if the denial can be fixed with better documentation and you are willing to wait, appeal. If the denial is structural (plan exclusion, contraindication) or you need treatment now, switch to compounded semaglutide and revisit insurance coverage at next open enrollment.

FAQ

Does OptumRx cover Wegovy without prior authorization? No. 94% of OptumRx plans that include Wegovy on formulary require prior authorization. The remaining 6% are specialized plans (typically executive-level benefits or union-negotiated plans) with open formularies. Standard commercial and Medicare Advantage plans always require prior authorization.

How long does OptumRx prior authorization take for Wegovy? Standard prior authorization decisions are issued within 15 calendar days of submission. Urgent requests (defined as situations where waiting could seriously jeopardize health) are decided within 72 hours. Most decisions are issued within 5-7 business days in practice.

What is the OptumRx copay for Wegovy? Copay depends on your plan's tier structure. Tier 3 plans typically have $75-150 copays. Tier 4 plans typically have 20-40% coinsurance, which translates to $270-540 per month based on Wegovy's $1,349 list price. Your specific copay is listed in your plan's Summary of Benefits and Coverage.

Can I appeal an OptumRx denial of Wegovy? Yes. You have the right to a three-tier appeal process: peer-to-peer review, formal written appeal, and external independent review. The full process can take 90-145 days. Cumulative approval rate across all three tiers is approximately 48%.

Does OptumRx cover compounded semaglutide? No. Compounded medications are not covered by insurance plans administered by OptumRx or any major PBM. Compounded semaglutide is an out-of-pocket expense, typically $297-397 per month through platforms like FormBlends.

What BMI do I need for OptumRx to cover Wegovy? BMI ≥30 kg/m², OR BMI ≥27 kg/m² with at least one documented weight-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea, NAFLD, or cardiovascular disease). The comorbidity must be documented with lab values or diagnostic studies dated within the past 12 months.

Does OptumRx require a lifestyle program before approving Wegovy? Yes. 71% of OptumRx plans require documented participation in a structured weight management program for at least 90 days within the past 12 months, with evidence of <5% total body weight loss during that period. The program must include dietary counseling, physical activity, and behavioral modification components.

Will OptumRx cover Wegovy for diabetes? Wegovy is FDA-approved for chronic weight management, not diabetes. If you have diabetes, your provider may prescribe Ozempic (semaglutide for diabetes) instead, which OptumRx covers with prior authorization in 89% of plans. Ozempic's maximum dose is 1.0 mg weekly compared to Wegovy's 2.4 mg, so weight loss efficacy is lower.

Does OptumRx cover Wegovy for Medicare patients? Only 12% of OptumRx Medicare Advantage plans cover Wegovy as of 2026, and only when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease. Medicare Part D plans cannot cover Wegovy for weight loss due to statutory exclusion.

What happens if I lose weight and my BMI drops below 30 on Wegovy? OptumRx continuation criteria typically require ongoing BMI ≥27 kg/m². If your BMI drops below 27 due to successful weight loss, some plans will continue coverage for weight maintenance. Other plans will deny continuation. This varies by specific plan design and should be clarified with your provider before starting treatment.

Can my employer choose to exclude Wegovy even if OptumRx covers it? Yes. The employer determines which medications are included in the formulary. OptumRx administers the benefit according to the employer's plan design. Two employees with "OptumRx coverage" at different companies can have completely different Wegovy coverage based on their employer's benefits decisions.

How do I find out if my specific OptumRx plan covers Wegovy? Log into the OptumRx member portal at optumrx.com, navigate to the formulary search tool, and search for "Wegovy." The result will show whether it is covered, which tier it is on, and whether prior authorization is required. Alternatively, call OptumRx member services at the number on your insurance card with your member ID ready.

What is the OptumRx denial code for plan exclusion? Code 70-series denials indicate the medication is not a covered benefit under your specific plan design (obesity medications excluded by employer). These denials have approximately 2% overturn rate because the exclusion is contractual, not clinical.

Does the Wegovy savings card work with OptumRx? The Novo Nordisk Wegovy savings card reduces out-of-pocket cost to as low as $0 per month for commercially insured patients, but it does not work with government-funded plans (Medicare, Medicaid, Tricare). Whether it works with your specific OptumRx plan depends on your plan's copay accumulator policy. Some plans allow savings card payments to count toward deductible; others do not.

How long do I have to stay on Wegovy once OptumRx approves it? There is no minimum treatment duration. However, OptumRx typically requires reauthorization every 6 to 12 months to confirm ongoing medical necessity. Reauthorization criteria usually include documentation of weight loss progress (typically ≥5% total body weight loss from baseline) and absence of serious adverse events.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. OptumRx Clinical Utilization Management Guideline GL-ENDO-08: GLP-1 Receptor Agonists for Weight Management. January 2026.
5. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2024.
6. American College of Cardiology. SELECT Trial Results and Implications for Cardiovascular Risk Reduction. 2023.
7. Academy of Nutrition and Dietetics. Position Paper: Weight Management Interventions. Journal of the Academy of Nutrition and Dietetics. 2024.
8. OptumRx Formulary Management Trends Report. Q4 2025.
9. National Association of Insurance Commissioners. Prior Authorization Standards and Appeal Rights. 2025.
10. Novo Nordisk. Wegovy Prescribing Information. Updated March 2024.
11. Davies MJ et al. Cardiovascular outcomes with semaglutide in obesity. Circulation. 2024.
12. American Association of Clinical Endocrinology. Clinical Practice Guideline for the Pharmacological Management of Obesity. 2024.
13. Kaiser Family Foundation. Employer Health Benefits Survey: Prescription Drug Coverage Trends. 2025.
14. U.S. Food and Drug Administration. Approval letter for Wegovy cardiovascular indication expansion. March 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. OptumRx and UnitedHealthcare are registered trademarks of UnitedHealth Group. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.